Repaglinide treatment amplifies first‐phase insulin secretion and high‐frequency pulsatile insulin release in Type 2 diabetes

Abstract

Repaglinide augments first-phase insulin secretion as well as high-frequency insulin secretory burst mass and amplitude during glucose entrainment in patients with Type 2 diabetes, while regularity of the insulin release process was unaltered.